Skip to main content
. 2023 Mar 13;15(6):1737. doi: 10.3390/cancers15061737

Figure 3.

Figure 3

The antitumor efficacy of low doses of NTX-301 in a preclinical model of AML. (AC), Bioluminescence images of tumor growth (A), quantitative measurements of the bioluminescence emission (photons/sec) (B), and body weight (C) of NOD/SCID mice (n = 8 per group) that were transplanted with luciferase-labeled MV4-11 cells and treated with NTX-301 (p.o., daily at 0.15, 0.30, or 0.45 mg/kg (mpk) in combination with tetrahydrouridine (THU, 42.0 mg/kg)) on day 42. *, p < 0.05.